/CYTK
CYTK Stock - Cytokinetics, Incorporated
Healthcare|BiotechnologyNASDAQ
$62.72+0.84%
+$0.52 (+0.84%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.81
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.96
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+26.5%upside
Target: $79.34
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CYTK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$62.09 – $63.35
TARGET (TP)$79.33
STOP LOSS$57.70
RISK/REWARD1:3.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.59
52W High$69.33
52W Low$29.31
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $18.47M | $7.53M | $94.59M | $70.43M | $55.83M |
| Gross Profit | $-320,934,000 | $-322,593,000 | $-146,225,000 | $-89,510,000 | $-41,123,000 |
| Gross Margin | -1737.2% | -4284.1% | -154.6% | -127.1% | -73.7% |
| Operating Income | $-536,248,000 | $-496,205,000 | $-324,202,000 | $-186,313,000 | $-93,943,000 |
| Net Income | $-589,526,000 | $-526,244,000 | $-388,955,000 | $-215,314,000 | $-127,290,000 |
| Net Margin | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% |
| EPS | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 |
Company Overview
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
71%
Hold / Neutral
4
29%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish4 Neutral/Bearish
Price Targets
$71
Average Target
↑ 12.6% Upside
Now
$49
Low
$71
Average
$95
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Goldman | Upgrade | Buy | $95 |
| July 30th 2025 | Raymond James | Resumed | Market Perform | - |
| April 24th 2025 | Barclays | Initiation | Overweight | $55 |
| February 7th 2025 | Citigroup | Initiation | Buy | $86 |
| January 22nd 2025 | Stifel | Initiation | Buy | $80 |
| November 8th 2024 | RBC Capital Mkts | Initiation | Outperform | $80 |
| August 13th 2024 | Goldman | Downgrade | Neutral | $60← $85 |
| January 24th 2024 | UBS | Downgrade | Neutral | $92← $61 |
| January 5th 2024 | Morgan Stanley | Downgrade | Equal Weight | $90← $60 |
| November 9th 2023 | Goldman | Initiation | Buy | $50 |
| November 7th 2023 | B. Riley Securities | Initiation | Buy | $66 |
| August 15th 2023 | SVB Securities | Initiation | Outperform | $58 |
| February 17th 2023 | BofA Securities | Initiation | Neutral | $49 |
| December 23rd 2022 | Needham | Reiterated | Buy | $58← $60 |
| December 20th 2022 | Truist | Initiation | Buy | $60 |
Earnings History & Surprises
CYTKBeat Rate
33%
Last 18 quarters
Avg Surprise
-6.9%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-1.54
Q4 2025
EPS Surprise History
Q1 24
-34.0%
$-1.38vs$-1.03
Q2 24
-14.7%
$-1.33vs$-1.16
Q3 24
-28.4%
$-1.31vs$-1.02
Q4 24
-7.1%
$-1.36vs$-1.27
Q1 25
+2.3%
$-1.26vs$-1.29
Q2 25
+3.5%
$-1.36vs$-1.41
Q3 25
+16.4%
$-1.12vs$-1.34
Q4 25
+3.1%
$-1.54vs$-1.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.47 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-1.59 | $-1.54 | +3.1% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-1.34 | $-1.12 | +16.4% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.41 | $-1.36 | +3.5% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-1.29 | $-1.26 | +2.3% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-1.27 | $-1.36 | -7.1% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-1.02 | $-1.31 | -28.4% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-1.16 | $-1.33 | -14.7% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-1.03 | $-1.38 | -34.0% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.72 | $-1.35 | -87.5% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-1.23 | $-1.34 | -8.9% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-1.24 | $-1.38 | -11.3% | ✗ MISS |
Q1 2023 | Mar 1, 2023 | $-1.22 | $-1.45 | -18.9% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-1.19 | $-1.28 | -7.6% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.04 | $-0.23 | +77.9% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.93 | $-1.02 | -9.7% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.89 | $-0.36 | +59.6% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.75 | $-0.95 | -26.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.65 | $-0.86 | -32.3% | ✗ MISS |
Latest News
CYTK stock has given up its prior gain. Cytokinetics shares were trading higher after the company announced that the FDA approved MYQORZO, 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
📈 PositiveBenzinga•Dec 19, 2025, 10:08 PM
Cytokinetics shares are trading higher after the company announced that the FDA approved MYQORZO, 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.
📈 PositiveBenzinga•Dec 19, 2025, 09:23 PM
Cytokinetics Shares Resume Trade
➖ NeutralBenzinga•Dec 19, 2025, 09:20 PM
Trading Halt: Halt status updated at 4:15:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 19, 2025, 09:15 PM
Cytokinetics Receives FDA Approval For MYQORZO Tablets To Treat Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
📈 PositiveBenzinga•Dec 19, 2025, 09:01 PM
Trading Halt: Halted at 1:50:12 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 19, 2025, 06:50 PM
Goldman Sachs Upgrades Cytokinetics to Buy, Raises Price Target to $95
📈 PositiveBenzinga•Dec 19, 2025, 04:49 PM
Cytokinetics Says MYQORZO Approved By China NMPA For Treatment Of Adults With NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy To Improve Exercise Capacity And Symptoms
📈 PositiveBenzinga•Dec 17, 2025, 12:36 PM
Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target
📈 PositiveBenzinga•Dec 12, 2025, 10:56 AM
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $87
📈 PositiveBenzinga•Nov 11, 2025, 03:21 PM
B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90
📈 PositiveBenzinga•Nov 10, 2025, 02:51 PM
Cytokinetics Presents Additional Data From MAPLE-HCM In Participants With LVOT Obstruction On Exercise Capacity In HCM
➖ NeutralBenzinga•Nov 10, 2025, 12:44 PM
CORRECTION: Cytokinetics Q3 Adj. EPS $(1.54) Beats $(1.58) Estimate, Sales $1.936M Miss $3.556M Estimate
➖ NeutralBenzinga•Nov 5, 2025, 11:44 PM
Cytokinetics Q3 EPS $(2.25) Misses $(1.57) Estimate, Sales $1.936M Miss $3.556M Estimate
📉 NegativeBenzinga•Nov 5, 2025, 09:02 PM
Cytokinetics shares are trading higher after Barclays maintained an Overweight rating on the stock and raised its price target from $71 to $82.
📈 PositiveBenzinga•Oct 6, 2025, 03:22 PM•Also:
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $82
📈 PositiveBenzinga•Oct 6, 2025, 01:00 PM•Also:
B of A Securities Maintains Neutral on Cytokinetics, Raises Price Target to $56
➖ NeutralBenzinga•Oct 2, 2025, 06:15 PM
Cytokinetics shares are trading higher. HC Wainwright & Co. reiterated its Buy rating on the stock and maintained its $120 price target.
📈 PositiveBenzinga•Sep 29, 2025, 07:44 PM
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 04:19 PM
Cytokinetics Presents Additional Data Related To Aficamten In Late Breaking Clinical Research Session At HFSA Annual Scientific Meeting 2025
➖ NeutralBenzinga•Sep 29, 2025, 11:36 AM
Frequently Asked Questions about CYTK
What is CYTK's current stock price?
Cytokinetics, Incorporated (CYTK) is currently trading at $62.72 per share. The stock has moved +0.84% today.
What is the analyst price target for CYTK?
The average analyst price target for CYTK is $79.33, based on 1 analyst.
What sector is Cytokinetics, Incorporated in?
Cytokinetics, Incorporated operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CYTK's market cap?
Cytokinetics, Incorporated has a market capitalization of $7.46 billion, making it a mid-cap company.
Does CYTK pay dividends?
No, Cytokinetics, Incorporated does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
AXSM
Axsome Therapeutics, Inc.
$152.65
Mkt Cap: $7.7B
CORT
Corcept Therapeutics Incorporated
$83.76
Mkt Cap: $8.8B
CRSP
CRISPR Therapeutics AG
$55.86
Mkt Cap: $4.9B
HALO
Halozyme Therapeutics, Inc.
$67.35
Mkt Cap: $7.9B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MRUS
Merus N.V.
$97.01
Mkt Cap: $7.4B
MTSR
Metsera, Inc.
$70.50
Mkt Cap: $7.4B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
Explore stocks similar to CYTK for comparison